Related Experiment Videos
Human prostate cancer progression models and therapeutic intervention
1Department of Urology, University of Virginia Health Sciences Center, Charlottesville, USA.
Hinyokika Kiyo. Acta Urologica Japonica
|January 22, 1998
Summary
Developed novel cellular models for prostate cancer progression and gene therapy. These models, LNCaP and ARCaP, demonstrate metastatic potential and response to targeted gene therapy, offering new avenues for cancer research.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Prostate cancer progression involves complex cellular interactions and genetic alterations.
- Existing cellular models have limitations in recapitulating metastatic potential and therapeutic responses.
- Androgen and estrogen signaling play critical roles in prostate cancer development and progression.
Purpose of the Study:
- To develop and characterize novel cellular models of human prostate cancer progression.
- To evaluate the efficacy of gene therapy strategies for prostate cancer treatment.
- To investigate the role of specific promoters in targeted gene delivery for cancer therapy.
Main Methods:
- Development of LNCaP and ARCaP cellular models reflecting prostate cancer progression and metastasis.
- In vivo inoculation of tumor cells into immunocompromised animal models.
- Gene therapy utilizing tissue-specific (prostate-specific antigen) and tumor-specific (osteocalcin) promoters to drive therapeutic gene expression.
- Evaluation of tumor growth inhibition and metastatic potential in response to gene therapy.
Main Results:
- LNCaP cells acquired tumorigenic and metastatic potential upon interaction with stromal cells, forming C4-2 subline.
- ARCaP cells, derived from metastatic disease, showed androgen- and estrogen-repressed growth but high metastatic potential.
- Gene therapy using prostate-specific antigen (PSA) and osteocalcin (OC) promoters demonstrated efficacy in inhibiting tumor growth.
- Osteocalcin-thymidine kinase (OC-TK) gene therapy showed potent tumor eradication in vitro and in vivo, particularly in androgen-independent cell lines.
Conclusions:
- The developed LNCaP and ARCaP models effectively recapitulate human prostate cancer progression and metastasis.
- Tissue-specific and tumor-specific promoters offer advantages for targeted gene therapy in prostate cancer.
- Osteocalcin-thymidine kinase (OC-TK) gene therapy, combined with acyclovir, shows promise for treating prostate cancer bone metastasis.